Satralizumab is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease, with Aquaporin 4-immunoglobulin G (AQP4-IgG+) playing a major role in its pathogenesis. Prof. Jeffrey Bennett (University of Colorado School of Medicine, Aurora, CO, USA) discusses the outcomes of SAkuraSky and SAkuraStar studies and what they have taught us about the efficacy and safety of satralizumab in AQP4-IgG+ NMOSD.
The abstract entitled ‘Long-term Efficacy of Satralizumab in Aquaporin-4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Open-label Extension Periods of SAkuraSky and SAkuraStar’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.
Questions:
- What did the SAkuraSky and SAkuraStar studies teach us about the efficacy and safety of satralizumab in AQP4-IgG+ NMOSD? (0:14)
- Could you tell us a little about the open-label extension study and its findings? (2:27)
- Since its approval, what has been the impact of satralizumab on clinical practice? (5:33)
Disclosures: Jeffrey Bennett is/has been a consultant for Roche/Genentech, Chugai Pharmaceuticals, Horizon, Mitsubishi-Tanabe, Reistone Bio, Abbvie, Clene Neuroscience, Alexion-AstraZeneca Rare Disease and Beigene; and has received grant/research support from National Institutes of Health, Novartis, Mallinckrodt Pharmaceuticals, and Alexion-AstraZeneca Rare Disease; and is on the advisory board for Roche/Genentech, and Alexion-AstraZeneca Rare Disease.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
